Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Autoimmune Myelofibrosis and Cytopenia Development

Acta Haematol; 2017 Sep 2; Piatek, et al

Publish date:: November 11, 2017

Autoimmune myelofibrosis (AIMF) plays a role in the development of cytopenias in patients with autoimmune disorders, according to a small study involving 12 individuals. Improvement occurred with immunosuppressive therapy. Investigators conducted a single-institution, retrospective chart review of patients with AIMF, looking at clinical presentations, therapies, and outcomes. Among the results:

All patients had detectable autoantibodies; most had concomitant autoimmune disorders.
Immunosuppresive therapy led to complete response of cytopenias in 4 patients and partial response in 3.
Partial response occurred in 1 patient post-splenectomy.
No myeloproliferative neoplasms were seen during a median follow-up of ~6 years.

Citation:

Piatek C, Vergara-Lluri M, Pullarkat V, et al. Autoimmune myelofibrosis: Clinical features, course, and outcome. Acta Haematol. 2017;138(3):129-137. doi:10.1159/000479103.

This Week's Must Reads

Consider potential cognitive complications prior to androgen deprivation therapy,

Diabetes raises risk of prostate cancer mortality in obese men,

Salivation inhibition fails to reduce radioiodine toxicity in prostate cancer,

Highest positive surgical margin predicts poor survival after prostatectomy,

Young minority men are underinformed about prostate cancer screening,

Must Reads in Hematologic Malignancies

Long-term ibrutinib data in older patients, Barr PM et al. Haematologica. 2018;103(9):1502-10

Prognostic Score System for Patients with PMF, J Clin Oncol; ePub 2017 Dec 9; Gugliemelli, et al

These Patients Are More Apt to Be Depressed, Ann Hematol; ePub 2017 Dec 7; Shreders, et al

Survival Length Shortest in These Patients with MF, Eur J Haematol; ePub 2017 Dec 11; Masarova, et al

The Value of Ruxolitinib Before and After AlloSCT, Blood; ePub 2017 Dec 7; Poulose, Malysz, et al